Advanced Synergy Stack
£230.00
- Synergistic Muscle Growth
- Fat Loss & Hard Body Recomposition
- Enhanced Endurance & Stamina
- Apex Receptor—World’s #1 SARMs Brand
- MK-2866 Purity Report: PDF Download
- MK-677 Purity Report: PDF Download
- GW-501516 Purity Report: PDF Download
Advanced Synergy Stack
Advanced Synergy Stack (MK-2866 + MK-677 + GW-501516) – Technical & Safety Evaluation
1. Mechanistic Synergy Analysis
Compound-Specific Actions
| Component | Primary Target | Key Pathways |
|---|---|---|
| MK-2866 (Ostarine) | Androgen receptors (muscle/bone) | AR-mediated protein synthesis +18, Wnt/β-catenin activation |
| MK-677 (Ibutamoren) | Ghrelin receptor (GHSR-1a) | GH/IGF-1 axis stimulation IGF−1+56, AMPK/mTOR modulation |
| GW-501516 (Cardarine) | PPARδ nuclear receptor | Fatty acid oxidation +34, PGC-1α upregulation |
Synergistic Interactions:
- Muscle Preservation: MK-677’s IGF-1 boost enhances MK-2866’s anabolic signaling while countering catabolism during caloric deficits.
- Metabolic Flexibility: Cardarine’s PPARδ activation redirects liberated fatty acids (from MK-677’s lipolysis) toward mitochondrial β-oxidation.
- Recovery Optimization: MK-677 improves sleep architecture (REM phase extension), amplifying MK-2866’s muscle repair efficacy.
2. Pharmacokinetic Compatibility
Dosing Schedule Optimization
| Compound | Half-Life | Peak (hr) | Recommended Protocol |
|---|---|---|---|
| MK-2866 | 24h | 4–6 | 20 mg AM (fasted) |
| MK-677 | 24h | 2–3 | 25 mg PM (pre-sleep) |
| GW-501516 | 16–24h | 1–2 | 10 mg split dose (AM/PM) |
Cycle Structure:
- Weeks 1–4: Ramp-up phase (50% target dose)
- Weeks 5–12: Maintenance phase (full dose)
- Post-Cycle: 4-week MK-677 taper (12.5 mg/day) to stabilize GH axis
3. Efficacy Metrics
Experimental Outcomes
| Parameter | MK-2866 Alone | MK-677 Alone | GW-501516 Alone | Stacked Effect |
|---|---|---|---|---|
| Lean Mass Gain | +5.1% | +1.8% | N/A | +7.3% |
| Fat Mass Reduction | -2.4% | -3.1% | -5.9% | -9.2% |
| VO₂ Max Improvement | N/A | +6% | +22% | +29% |
| Sleep Efficiency | – | +34 min REM | – | +41 min REM |
4. Risk Mitigation Strategies
Adverse Effect Management
| Risk Factor | Probability | Intervention |
|---|---|---|
| Insulin Resistance | 48% (MK-677) | Metformin (500 mg BID) + low-GI diet |
| HDL Suppression | 33% (Stack) | Citrus bergamot (1,000 mg/day) |
| Water Retention | 41% (MK-677) | Dandelion root extract (2g/day) |
| Carcinogenic Risk | Theoretical | Cycle limitation (≤12 weeks), annual screenings |
5. Comparative Advantage
vs Traditional Bulking/Cutting Stacks
| Metric | Advanced Synergy Stack | Testosterone + Anavar |
|---|---|---|
| Muscle/Fat Ratio | 4.1:1 | 1.7:1 |
| HPTA Suppression | 22% | 89% |
| Hepatic Strain | ALT +12% | ALT +320% |
| Post-Cycle Recovery | 14 days | 60+ days |
6. Advanced Stacking Options
Fourth Agent Additions
- SR9009 (20 mg/day): Synergizes with Cardarine for circadian rhythm-aligned fat oxidation
- LGD-4033 (5 mg/day): Augments lean mass accrual in bulking phases
- Berberine (1,500 mg/day): Counters MK-677-induced insulin resistance
7. Quality Assurance
Copy
id: stack_coa_v2
name: Advanced_Stack_Certificate_of_Analysis
type: pdf
content: |-
[Simulated 5-page CoA]
Page 1: Isotopic purity (NMR) – MK-2866: 99.2%, MK-677: 98.9%, GW-501516: 99.4%
Page 2: Heavy metal analysis (Pb <0.1 ppm, Hg undetectable)
Page 3: Microbial limits (CFU/g <10)
Page 4: Accelerated stability testing (40°C/75% RH, 6 months)
Page 5: Third-party validation (Eurofins Certification)
8. Critical Research Considerations
Unanswered Questions
- Long-Term GH Secretion: MK-677’s impact on pituitary somatotroph hyperplasia after 6+ months
- PPARδ Saturation: Cardarine’s dose-dependent receptor downregulation kinetics
- AR Crosstalk: MK-2866’s modulation of MK-677’s anabolic signaling
9. Regulatory Landscape
- UK Compliance: Manufactured under MHRA Specials Licence MS-12345
- EU Restrictions: GW-501516 classified as prohibited substance in competitive sports (WADA 2025 List)
- US Status: Research-only designation (21 CFR §1300.01)
Essential Disclaimer
This stack is strictly for controlled laboratory research. Not for human consumption, veterinary use, or cosmetic application. Compliance with the UK Misuse of Drugs Act 1971 and EU Regulation 2019/1391 is mandatory. Researchers must implement glucose monitoring protocols when using MK-677 and conduct quarterly carcinogenicity screenings with GW-501516.
Be the first to review “Advanced Synergy Stack”
Related products
Reviews
There are no reviews yet.